Bio-Rad forecasts 2026 currency-neutral revenue growth of (-3%) to +0.5% while targeting $30M-$35M net cost savings by end of 2027 — See source for full details.
$BIO
Price history, market instrument context, member research, and related headlines in one place.
BIO key statistics
NYSEUSD
52-week range
$236.7384%$396.23
Latest session $352.46–$371.31Bio-Rad Laboratories, Inc. (BIO) is a stock instrument quoted on NYSE in USD. The most recently published price is $369.95, up $6.45 (1.77%) from the previous close of $363.50. It has traded between $352.46 and $371.31 in the latest session. Over the past year it has ranged from $236.73 to $396.23, leaving it in the upper quarter of its 52-week range (84%). Reported volume for the session was 167.4K. Figures are the latest published by the exchange feed and are not a recommendation.
Primary market bars from Yahoo Finance · Extended-hours prints appear when supplied by the venue · Interactive charts powered by TradingView Lightweight Charts™ · Not a recommendation
WOOK AIASK ANYTHING · NEVER ADVISES
Meet Wook AI, your friendly assistant. Ask how something works, about any company, fund or coin, or have it do the math — live figures come from this site’s own lookups, and you’ll see which ones it used.
Source-linked intelligence
Related news
Bio-Rad Q2 2026 slides: earnings beat masks ongoing challenges — See source for full details.
Bio-Rad Q2 2026 slides: earnings beat, shares fall on outlook — See source for full details.
Earnings call transcript: Bio-Rad tops Q2 2026 estimates, shares fall after hours — See source for full details.
Bio-Rad Laboratories, Inc. Non-GAAP EPS of $2.62 beats by $0.87, revenue of $651M beats by $27.01M — See source for full details.
Bio-Rad earnings up next: Can diagnostics stabilize amid headwinds? — See source for full details.
Bio-Rad earnings on deck: Revenue growth amid margin pressure — See source for full details.
Loading $BIO research…